Genzyme Corporation (GENZ)’s Multiple Sclerosis Franchise Featured at ECTRIMS
9/26/2013 6:50:39 AM
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) announced today that new data from its Aubagio® (teriflunomide) and Lemtrada™ (alemtuzumab) clinical development programs will be presented during the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) and the 18th Annual Conference of Rehabilitation in MS (RIMS) to be held in Copenhagen, Denmark, October 2-5.
Help employers find you! Check out all the jobs and post your resume.
comments powered by